498 related articles for article (PubMed ID: 31984872)
1. Methamphetamine Use and Antipsychotic-related Extrapyramidal Side-effects in Patients with Psychotic Disorders.
Temmingh HS; van den Brink W; Howells F; Sibeko G; Stein DJ
J Dual Diagn; 2020; 16(2):208-217. PubMed ID: 31984872
[No Abstract] [Full Text] [Related]
2. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study.
McKetin R; Lubman DI; Baker AL; Dawe S; Ali RL
JAMA Psychiatry; 2013 Mar; 70(3):319-24. PubMed ID: 23303471
[TBL] [Abstract][Full Text] [Related]
3. The relationship between illicit amphetamine use and psychiatric symptom profiles in schizophrenia and affective psychoses.
Voce A; McKetin R; Burns R; Castle D; Calabria B
Psychiatry Res; 2018 Jul; 265():19-24. PubMed ID: 29680513
[TBL] [Abstract][Full Text] [Related]
4. Risks of psychosis in methamphetamine users: cross-sectional study in Thailand.
Lamyai W; Pono K; Indrakamhaeng D; Saengsin A; Songhong N; Khuwuthyakorn P; Sribanditmongkol P; Junkuy A; Srisurapanont M
BMJ Open; 2019 Oct; 9(10):e032711. PubMed ID: 31615802
[TBL] [Abstract][Full Text] [Related]
5. Predictors of methamphetamine psychosis: history of ADHD-relevant childhood behaviors and drug exposure.
Salo R; Fassbender C; Iosif AM; Ursu S; Leamon MH; Carter C
Psychiatry Res; 2013 Dec; 210(2):529-35. PubMed ID: 23896355
[TBL] [Abstract][Full Text] [Related]
6. Polysubstance-induced relapse of schizoaffective disorder refractory to high-dose antipsychotic medications: a case report.
Tucker MG; Kekulawala S; Kent M; Mostafa S; Harvey R
J Med Case Rep; 2016 Sep; 10(1):242. PubMed ID: 27599617
[TBL] [Abstract][Full Text] [Related]
7. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole.
Brown ES; Jeffress J; Liggin JD; Garza M; Beard L
J Clin Psychiatry; 2005 Jun; 66(6):756-60. PubMed ID: 15960570
[TBL] [Abstract][Full Text] [Related]
8. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
9. Monitoring the prevalence of methamphetamine-related presentations at psychiatric hospitals in Cape Town, South Africa.
Plüddemann A; Dada S; Parry CD; Kader R; Parker JS; Temmingh H; van Heerden S; de Clercq C; Lewis I
Afr J Psychiatry (Johannesbg); 2013 Jan; 16(1):45-9. PubMed ID: 23417636
[TBL] [Abstract][Full Text] [Related]
10. Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospective cohort study.
Rafizadeh R; Frankow L; Mahmood H; Poonia S; Mathew N; Danilewitz M; Bousman CA; Honer WG; Schütz CG
J Psychopharmacol; 2023 Oct; 37(10):1040-1048. PubMed ID: 37539972
[TBL] [Abstract][Full Text] [Related]
11. The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia.
Sulaiman AH; Said MA; Habil MH; Rashid R; Siddiq A; Guan NC; Midin M; Nik Jaafar NR; Sidi H; Das S
Compr Psychiatry; 2014 Jan; 55 Suppl 1():S89-94. PubMed ID: 23433219
[TBL] [Abstract][Full Text] [Related]
12. Primary and substance-induced psychotic disorders in methamphetamine users.
Hides L; Dawe S; McKetin R; Kavanagh DJ; Young RM; Teesson M; Saunders JB
Psychiatry Res; 2015 Mar; 226(1):91-6. PubMed ID: 25677394
[TBL] [Abstract][Full Text] [Related]
13. Clinical course and outcomes of methamphetamine-dependent adults with psychosis.
Glasner-Edwards S; Mooney LJ; Marinelli-Casey P; Hillhouse M; Ang A; Rawson R;
J Subst Abuse Treat; 2008 Dec; 35(4):445-50. PubMed ID: 18294802
[TBL] [Abstract][Full Text] [Related]
14. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patients.
Sramek J; Roy S; Ahrens T; Pinanong P; Cutler NR; Pi E
Hosp Community Psychiatry; 1991 Jun; 42(6):590-2. PubMed ID: 1677921
[TBL] [Abstract][Full Text] [Related]
16. Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders.
McKetin R; Baker AL; Dawe S; Voce A; Lubman DI
Psychiatry Res; 2017 May; 251():349-354. PubMed ID: 28282630
[TBL] [Abstract][Full Text] [Related]
17. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol.
Oosthuizen PP; Emsley RA; Maritz JS; Turner JA; Keyter N
J Clin Psychiatry; 2003 Sep; 64(9):1075-80. PubMed ID: 14628983
[TBL] [Abstract][Full Text] [Related]
18. Hostility among methamphetamine users experiencing psychotic symptoms.
McKetin R; McLaren J; Lubman DI; Hides L
Am J Addict; 2008; 17(3):235-40. PubMed ID: 18464001
[TBL] [Abstract][Full Text] [Related]
19. Sex Differences in Methamphetamine Use and Dependence in a Thai Treatment Center.
Rungnirundorn T; Verachai V; Gelernter J; Malison RT; Kalayasiri R
J Addict Med; 2017; 11(1):19-27. PubMed ID: 27649265
[TBL] [Abstract][Full Text] [Related]
20. Tardive dyskinesia in affective disorders.
Kane JM
J Clin Psychiatry; 1999; 60 Suppl 5():43-7; discussion 48-9. PubMed ID: 10192407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
